Gilead Sciences, Inc.
About Gilead Sciences, Inc.
Gilead Sciences is a biopharmaceutical company that discovers, develops, and commercializes innovative therapeutics in areas of unmet medical need. The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North America, Europe and Australia.
2098 articles with Gilead Sciences, Inc.
-
Gilead Sciences, Inc. to Present at Three Upcoming Investor Conferences
11/6/2008
-
Gilead Sciences, Inc. Announces Two-Year Data from Pivotal Phase III Studies Evaluating Viread(R) for Chronic Hepatitis B
11/3/2008
-
Gilead Sciences, Inc. to Present at the Oppenheimer 19th Annual Healthcare Conference on Tuesday, November 4
10/31/2008
-
Gilead Sciences, Inc. Signs Agreement with EFI to Acquire Building and Associated Land Bordering Gilead's Foster City Campus for $137.5 Million
10/24/2008
-
Gilead Sciences, Inc. Announces Third Quarter 2008 Financial Results
10/17/2008
-
FDA Wants More Data on Gilead Sciences, Inc. Cystic Fibrosis Drug
9/17/2008
-
Seigo Izumo, MD Joins Gilead Sciences, Inc. as Senior Vice President, Cardiovascular Therapeutics
9/12/2008
-
Gilead Sciences, Inc. Sciences to Present at Two Upcoming Investor Conferences
9/11/2008
-
Brazil Rejects Gilead Sciences, Inc.'s AIDS Drug Patent
9/4/2008
-
Gilead Sciences, Inc. to Present at the Thomas Weisel Partners Healthcare Conference on Wednesday, September 3
8/28/2008
-
Gilead Sciences, Inc. Plans 1,900 New Jobs; Biotech Company Moves to Double Foster City Headquarters
8/25/2008
-
Gilead Sciences, Inc. AIDS Drugs Will Be Tested To See If They Can Prevent HIV
8/4/2008
-
Richard J. Whitley, MD Joins Gilead Sciences, Inc.'s Board of Directors
7/31/2008
-
Gilead Sciences, Inc. Initiates Phase III Clinical Trial of Elvitegravir, an Investigational Integrase Inhibitor for HIV
7/23/2008
-
Gilead Sciences, Inc. Announces Second Quarter 2008 Financial Results
7/18/2008
-
Gilead Sciences, Inc. to Release Second Quarter 2008 Financial Results on Thursday, July 17, 2008
7/9/2008
-
Monogram Biosciences Collaborates with Gilead Sciences, Inc. for Elvitegravir
6/18/2008
-
Gilead Sciences, Inc. Announces Interim 12-Month Phase III Study Results for Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis; Aztreonam Lysine Well Tolerated
6/13/2008
-
Gilead Sciences, Inc. to Present at the 29th Annual Goldman, Sachs & Co. Global Healthcare Conference on Wednesday, June 11
6/5/2008
-
Boehringer Ingelheim Corporation, Gilead Sciences, Inc. Agree to AIDS Drug Price Freeze
6/3/2008